<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Seres Therapeutics, Inc.

    Seres Therapeutics, Inc.

    Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing ...

    Seres Therapeutics, Inc. is a microbiome therap...

    Filing Type:    PU
    Eyegate Pharmaceuticals, Inc.

    Eyegate Pharmaceuticals, Inc.

    EyeGate is developing and commercializing products for treating diseases and disor...

    EyeGate is developing and commercializing produ...

    Filing Type:    PU
    Pulse Biosciences, Inc

    Pulse Biosciences, Inc

    Pulse Biosciences is a bioelectric medicine company pursuing commercial introducti...

    Pulse Biosciences is a bioelectric medicine com...

    Filing Type:    PU
    Guardion Health Sciences, Inc.

    Guardion Health Sciences, Inc.

    Guardion Health Sciences is at the forefront of early detection, intervention and ...

    Guardion Health Sciences is at the forefront of...

    Filing Type:    PU
    Lonza Group AG

    Lonza Group AG

    Lonza is an integrated solutions provider that creates value along the Healthcare ...

    Lonza is an integrated solutions provider that ...

    Filing Type:    PU
    Trinity Biotech plc

    Trinity Biotech plc

    Trinity Biotech specializes in the development, manufacture and marketing of diagn...

    Trinity Biotech specializes in the development,...

    Filing Type:    PU
    Trillium Therapeutics Inc.

    Trillium Therapeutics Inc.

    Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...

    Trillium Therapeutics Inc. is a clinical stage ...

    Filing Type:    PU
    Cellectis S.A.

    Cellectis S.A.

    Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...

    Cellectis is a clinical-stage biopharmaceutical...

    Filing Type:    PU
    Merck KGaA

    Merck KGaA

    Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...

    Merck KGaA, Darmstadt, Germany, a leading scien...

    Filing Type:    PU
    PDS Biotechnology Corporation

    PDS Biotechnology Corporation

    PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to trea...

    PDS Biotechnology has a growing pipeline of cli...

    Filing Type:    PU
    Gritstone Oncology, Inc.

    Gritstone Oncology, Inc.

    Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...

    Gritstone Oncology is developing tumor-specific...

    Filing Type:    PU
    Global Cancer Technology, Inc

    Global Cancer Technology, Inc

    Global Cancer Technology (“GCT”) is an emerging medical technology company with nu...

    Global Cancer Technology (“GCT”) is an emerging...

    Amount Raised:    $82,711.00
    Fundraising Status:    EC
    Filing Type:    CF
    ©2026 National Investor Network. All Rights Reserved.